Your Solutions
BIOMEDTRACKER
Real-time Event Tracking & Drug Development Analysis
管线研发追踪、获批前景分析、商业资讯、调研报告
MEDTECH INSIGHT
Latest News, Analysis & Strategic Insights on Global Med-tech Sector
全球资讯及见解 - 医疗器械产业
Meet the team
Liang Chen (China)
Account Manager
Citeline
Robert Wu (APAC)
Client Success Manager
Citeline
Training & Help
We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]
我们提供各产品的使用培训支持，请点击下列查阅相关培训资源，若有特定培训需求或安排则可联系：[email protected]
For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:
若有任何登录问题，请切换至Meet the Team版面并联系对接服务团队，或可联系全球/亚太客服团队：
Global - [email protected] (English only)
APAC - [email protected] (via English/Chinese)
Require Research Support?
Ask-the-Analyst™
Ask-the-Analyst™
Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.
作为重点合作伙伴，贵司用户均可无限量使用Ask-the-Analyst™分析师咨询服务！分析师团队将会在24小时内回复（工作日）并为您提供信息收集或专业见解，最终助您做出更快、更明智的业务决策。
Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.
由业界专家组成的分析师团队将结合内部数据与公开领域资源为您提供支持，您的个人资讯与提问内容均会被严格保密。
Latest Monthly Newsletter
Edition: December 2025
EDITORIAL CONTENTS (incl. Podcasts, Webinars)
- Notable Podcast: Drug Fix: Understanding the US FDA’s CDER Leadership Shuffle
- Notable Webinar: 2026 Preview Webinar (Jan 22, 2026)
- Notable Webinar: Inside #JPM2026: The Stories Behind the Summit (Feb 5, 2026)
DEALS & FINANCING (incl. M&As, Licensing, Financing)
- Notable M&A: BioMarin to Acquire Amicus Therapeutics for $4.8B
- Notable M&A: Sanofi to Acquire Dynavax for $2.2B
- Notable Licensing: Pfizer Enters into Exclusive Collaboration and License Agreement with Fosun Pharma’s YaoPharma for GLP-1R Agonist YP05002 totalling $2.1B
- Notable Licensing: Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 totalling $2B
- Notable Financing: Syremis Therapeutics Raises $165M in Series A Round
- Notable Financing: Medline Nets $6.1B in Upsized IPO
KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)
- Notable Analysis: BeOne Medicines | BGB-16673 | CLL (Phase 3): “BeOne's BGB-16673 matches bexobrutideg on response rates in heavily pre-treated CLL but loses out on safety profile…”
- Notable Analysis: Galapagos | GLPG5101 | Mantle Cell Lymphoma (Phase 2): “GLPG5101 continues to impress in mantle cell lymphoma despite the windup of Galapagos' cell therapy unit…”
- Notable Analysis: Ultragenyx | BPS804 | Osteogenesis Imperfecta (Phase 3): “Setrusumab Fails in Pivotal Trials for Osteogenesis Imperfecta, Casting Doubt on Future Development…”
- Notable Analysis: uniQure | AMT-130 | Huntington's Disease (Phase 2): “FDA deems AMT-130 BLA data insufficient, leaving path forward in Huntington's disease unclear…”
RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)
- Notable Report: 2025 Post-ASH Report
- Notable Report: In Vivo Outlook 2026
- Notable Report: 2026 Investor & Medical Conference Calendar
- Notable Report: Epi & Market Forecast: Amyotrophic Lateral Sclerosis (ALS)
- Notable Report: Epi & Market Forecast: Autism Spectrum Disorders
- Notable Report: Epi & Market Forecast: Cervical Cancer
- Notable Report: Epi & Market Forecast: Glioblastoma
- Notable Report: KOL Interview: Schizophrenia | ALS | Spinal Muscular Atrophy | Systemic Lupus Erythematosus
Latest Editorial Podcasts
